Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial.

[1]  Glenn J Jaffe,et al.  Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. , 2013, American journal of ophthalmology.

[2]  Emily Y. Chew,et al.  Macular telangiectasia type 2 , 2013, Progress in Retinal and Eye Research.

[3]  Catherine Egan,et al.  The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia. , 2012, Investigative ophthalmology & visual science.

[4]  Weng Tao,et al.  Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. , 2012, Investigative ophthalmology & visual science.

[5]  Catherine Egan,et al.  "En face" OCT imaging of the IS/OS junction line in type 2 idiopathic macular telangiectasia. , 2012, Investigative ophthalmology & visual science.

[6]  Krzysztof Kiryluk,et al.  Identification of a Potential Susceptibility Locus for Macular Telangiectasia Type 2 , 2012, PloS one.

[7]  Brian C. Toy,et al.  TREATMENT OF NONNEOVASCULAR IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 WITH INTRAVITREAL RANIBIZUMAB: Results of a Phase II Clinical Trial , 2012, Retina.

[8]  P. Sieving,et al.  CNTF and retina , 2012, Progress in Retinal and Eye Research.

[9]  F. Holz,et al.  Erratum: Monthly ranibizumab for nonproliferative macular telangiectasia type 2: A 12-month prospective study (American Journal of Ophthalmology (2011) 151:5 (876-886)) , 2011 .

[10]  P. Charbel Issa,et al.  Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. , 2011, American journal of ophthalmology.

[11]  Katherine E. Talcott,et al.  Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment. , 2011, Investigative ophthalmology & visual science.

[12]  George A. Williams,et al.  Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration , 2011, Proceedings of the National Academy of Sciences.

[13]  R. Guymer,et al.  Perifoveal müller cell depletion in a case of macular telangiectasia type 2. , 2010, Ophthalmology.

[14]  R. Lira,et al.  Intravitreous ranibizumab as treatment for macular telangiectasia type 2. , 2010, Archives of ophthalmology.

[15]  Robert Finger,et al.  Structure-Function Correlation of the Human Central Retina , 2010, PloS one.

[16]  M. Lavail,et al.  CNTF Induces Regeneration of Cone Outer Segments in a Rat Model of Retinal Degeneration , 2010, PloS one.

[17]  G. Rubin,et al.  STRUCTURAL AND FUNCTIONAL CHANGES OVER TIME IN MacTel PATIENTS , 2009, Retina.

[18]  G. Rubin,et al.  Test-retest variability of microperimetry using the Nidek MP1 in patients with macular disease. , 2009, Investigative ophthalmology & visual science.

[19]  Oscar Yanes,et al.  Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress. , 2009, The Journal of clinical investigation.

[20]  Hendrik P N Scholl,et al.  Reading performance is reduced by parafoveal scotomas in patients with macular telangiectasia type 2. , 2009, Investigative ophthalmology & visual science.

[21]  M. Bach,et al.  ISCEV Standard for full-field clinical electroretinography (2008 update) , 2009, Documenta Ophthalmologica.

[22]  Tunde Peto,et al.  The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project. , 2008, Investigative ophthalmology & visual science.

[23]  I. Maruko,et al.  Early morphological changes and functional abnormalities in group 2A idiopathic juxtafoveolar retinal telangiectasis using spectral domain optical coherence tomography and microperimetry , 2008, British Journal of Ophthalmology.

[24]  F. Holz,et al.  Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia , 2008, British Journal of Ophthalmology.

[25]  R. Lund,et al.  Intraocular CNTF reduces vision in normal rats in a dose-dependent manner. , 2007, Investigative ophthalmology & visual science.

[26]  Edoardo Midena,et al.  Microperimetry and fundus autofluorescence in patients with early age-related macular degeneration , 2007, British Journal of Ophthalmology.

[27]  P. Sieving,et al.  Regulation of Rod Phototransduction Machinery by Ciliary Neurotrophic Factor , 2006, The Journal of Neuroscience.

[28]  J. F. Arevalo,et al.  Indocyanine-green-mediated photothrombosis (IMP) with intravitreal triamcinolone acetonide for macular edema secondary to group 2A idiopathic parafoveal telangiectasis without choroidal neovascularization: a pilot study , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.

[29]  Weng Tao,et al.  Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[30]  T. Das,et al.  Bilateral sequential photodynamic therapy for sub-retinal neovascularization with type 2A parafoveal telangiectasis. , 2005, American journal of ophthalmology.

[31]  U. Mansmann,et al.  Automated analysis of digital fundus autofluorescence images of geographic atrophy in advanced age-related macular degeneration using confocal scanning laser ophthalmoscopy (cSLO) , 2005, BMC ophthalmology.

[32]  P. Sieving,et al.  Encapsulated cell-based intraocular delivery of ciliary neurotrophic factor in normal rabbit: dose-dependent effects on ERG and retinal histology. , 2004, Investigative ophthalmology & visual science.

[33]  B. Garretson,et al.  Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. , 2003, Retina.

[34]  M. Lavail,et al.  Protection of mouse photoreceptors by survival factors in retinal degenerations. , 1998, Investigative ophthalmology & visual science.

[35]  C. Gravel,et al.  Adenovirus-mediated gene transfer of ciliary neurotrophic factor can prevent photoreceptor degeneration in the retinal degeneration (rd) mouse. , 1997, Human gene therapy.

[36]  S. Friedman,et al.  Subretinal hemorrhage after grid laser photocoagulation for idiopathic juxtafoveolar retinal telangiectasis. , 1993, Ophthalmic surgery.

[37]  M. Lavail,et al.  Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  F. Ferris,et al.  New visual acuity charts for clinical research. , 1982, American journal of ophthalmology.

[39]  J. Gass,et al.  Idiopathic juxtafoveolar retinal telangiectasis. , 1982, Archives of ophthalmology.

[40]  K. Rohrschneider,et al.  Microperimetry--comparison between the micro perimeter 1 and scanning laser ophthalmoscope--fundus perimetry. , 2005, American journal of ophthalmology.